IRP Health is a research-driven organization, featuring a research collaboration with Monash University. Monash University is consistently ranked in the top one per cent of world universities and is top 3 in the world for Pharmacy and Pharmacology according to QS ranking, just behind University of Oxford and Harvard University. Monash University is active in over 150 fields of research across its 10 faculties. Many ideas developed at Monash - such as a new Malaria vaccine and 3D-printed engines - have been commercialized and are making a difference to the world.
Learn more about Monash University research.
At IRP Health, we are discovering natural, plant-derived compounds to create formulations with antimicrobial properties. We are using our proprietary formulations to replace the use of antibiotics in animal production. And we combine our formulations with existing human drugs to improve their efficacy in killing antibiotic resistance strains.
Zhicheng is a distinguished scientist with an extensive international academic and industry network. Zhicheng holds a Doctor of natural science degree from Swiss Federal Institute of Technology. He was trained in Harbin Medical University, University of Science and… Technology of China and Beijing Medical University as both a medical and Ph.D. student. He was a postdoctoral fellow of University of California, Irvine, University of Southern California, University of Rochester in USA, McGill University in Canada, and University Hamburg in Germany. He joined Singapore General Hospital in 2000 as a principal investigator in 2004, and Hong Kong University in 2008 as an Associate Professor. He joined GlaxoSmithKline in 2009 as a Director of Innovative Research and joined Monash University in 2010 as a full Professor.
Miguel is an international business professional with more than 20 years of experience in the life sciences industry. He has held executive positions in Fortune 500 companies, including Monsanto, now Bayer Crop Sciences. Miguel has been Chairman, President, Chief Executive Officer, Chief Financial Officer or Chief Operating Officer of growth-stage, venture capital backed companies. He has extensive experience in strategy, launching novel products in developed and emerging markets, mergers and acquisitions, and capital formation. He brings a true global perspective having led global organizations and lived in Switzerland, Spain, The Netherlands, France, Japan, Mexico and the US. Miguel received his MBA with honors from the Rotterdam School of Management in the Netherlands and his BS with honors from the Monterrey Institute of Technology and Higher Education.
Michael is the former Vice-President and General Manager for Zoetis, Australia and New Zealand. With more than 35 years of experience in the animal health industry, Mike brings with him expertise and relationships to support the commercial strategy of IRP Health. He is currently the non-executive director at Apiam Animal Health and former NE director of the Sheep CRC.
Nick Birrell has over 35 years of experience in science, technology and finance. He has a Ph.D. degree in Mathematical Physics, which led him by way of the computer industry, and being the CEO of a successful technology start-up, to being one of the first professional quant investors in an Australian investment bank. He was the founding CEO of what is now Credit Suisse Asset Management Australia and was the second CEO of County Investment Management. Following the acquisition of County by global investment management company INVESCO, he became Regional Director – Asia Pacific of INVESCO, with funds management teams in 6 countries throughout the region. Subsequently Nick became a Venture Executive with venture capital company, Innovation Capital, to which he remains an advisor. Nick has been a Professorial Fellow and adjunct Professor at Monash University Faculty of Business and Economics. In 2007 he launched the successful Monash Master of Business (Science & Technology) degree, which teaches Science and Technology graduates the business of science, including commercialization of scientific discoveries.
Colin is currently Professor and Head of the Department of Pharmaceutical Biology (Faculty of Pharmacy and Pharmaceutical Sciences) in the Monash Institute of Pharmaceutical Sciences, as well as Executive Member of the Drug Discovery Biology Theme. He has worked in this field for over 30 years, in both basic and applied sciences. In particular, Colin has worked on the use of the cell and molecular biological models in mechanistic investigations of neurological and neurodegenerative diseases, leading to improving models for drug discovery, and problems in delivery of therapeutic agents, notably in oral absorption of poorly water-soluble drugs, and delivery of nucleic acids for vaccination and gene therapy. He has been named on the Thomson Reuters list of Highly Cited Researchers, placing him among the top one per cent of the most highly cited researchers in the world within their subject area.
David has a degree in Veterinary Science and has held positions in major animal health companies for over 35 years. These roles included research and regulatory, marketing, sales management and general management. David has worked for Elanco, Fort Dodge, Pfizer and Zoetis. He has held roles which will add value to both the commercial and research and regulatory areas of IRP Health. He has also lived and worked in the US as well as having worked extensively in Asia and New Zealand. David has worked in the production animal sectors as well as small animal areas.
David Faulkner graduated from the University of Sydney in 1981, completing a Bachelor of Agricultural Economics degree. He has worked in the Animal Health and Feed Industries since graduation in Australia, Brazil, China and throughout South-East Asia. His experience includes roles in sales, marketing, General Management and Regional Management with leading companies in the Animal Health and Feed Additive/Ingredients sectors.
Dr. Zhiyong is the research director at IRP Health. He joined the team in 2016 from Monash University where he previously worked on the Phytochemical therapy for neurodegeneration diseases. Zhiyong studied Biotechnology at Huazhong Agriculture University where he received his bachelor’s degree in China. He completed his PhD in Biophysics and has published more than 10 peer-reviewed paper. Zhiyong worked as a researcher at GlaxoSmithKline’s Shanghai R&D center before he started his PhD studies.
Mr Xiao Sa is the Finance and Operation Director at IRP Health. Mr. Xiao Joined IRP in 2016 from Vancouver, where he was working as controller at a real estate development firm. Mr. Xiao studied economics at the University of Toronto. Mr. Xiao participated in the largest research funding partnership ever negotiated between an Australian university and China, resulting in the creation of a research institute in Shenzhen, China.
All rights reserved. Certain statements may not be applicable in all geographic regions. Product labelling and associated claims may differ based upon regulatory requirements. Our products are sold in countries where regulatory approval has been granted. For a listing of countries where our products are sold, please contact us.
See our Terms and Conditions